A Phase 1 interventional study of INTP5 and US Neulasta in Immunogenicity and Healthy Volunteers, sponsored by Intas Pharmaceuticals, Ltd.. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-04.
Sponsored by Intas Pharmaceuticals, Ltd. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study was an assessor-blind, balanced, parallel, randomized, two-treatment, comparative immunogenicity study of multiple doses of subcutaneous (SC) Pegfilgrastim injection (6 mg/0.6 mL; Intas Pharmaceuticals Ltd. proposed biosimilar INTP5 compared to innovator product, US-Neulasta) in healthy, adult, human subjects under fed conditions.
Intas Pharmaceuticals, Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In case of female subjects:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
Combination Product: INTP5
US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
Combination Product: US Neulasta
INTP5, a pegfilgrastim biosimilar to US Neulasta.
US Neulasta: FDA approved pegfilgrastim innovator product.
Immunogenicity Screening Incidence to Detect the Presence of Anti-PegG-CSF Antibodies.
Immunogenicity (anti-drug antibody; ADA) data is presented for all subjects' samples collected and a descriptive analysis is provided for immunogenicity (ADA) data. Percentage incidence within + 10% of the expected ADA positivity incidence of Test (6% ADA in Test is anticipated from literature) is not considered clinically significant. Evaluation of immunogenicity is carried out in a tiered fashion: 1. Screening assay to assess if samples were positive or negative for anti-PegG-CSF. 2. Confirmatory assays for samples that were positive in the screening assay. The confirmatory assays assessed if antibodies were specific for INTP5, Neulasta, PEG and/or filgrastim. 3. Titer assay was performed to determine titer of the anti-PEG-GCSF antibody samples. 4. Neutralizing antibody (NAb) assay for those samples that were positive in the confirmatory assays to assess the neutralizing capability of the antibody to inhibit pegfilgrastim activity.
Time frame: Samples (8 mL each) were withdrawn at screening, at pre-dose and at 336 (D-15, Week 2), 504 (D-22, Week 3, within 60 minutes before 2nd dose), 840 (D-36, Week 5), 1176 (D-50, Week 7), 1680 (D-71, Week 10) and 2016 (D-85, Week 12) hours after first dose.
PK Endpoints: Pegfilgrastim C[Max]
Pharmacokinetic (PK) properties of the test and reference formulations were assessed by measuring serum Pegfilgrastim concentration. Maximum measured serum concentration, calculated from the serum concentration vs. time profile of the individual subjects.
Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
PK Endpoints: Pegfilgrastim AUC[0-t]
Area under the serum concentration vs. time curve, calculated by linear trapezoidal rule from measured data points from the time zero to the time of last quantified concentration.
Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
PK Endpoints: Pegfilgrastim AUC[0-∞]
Area under the serum concentration versus time curve from time zero to infinity. Where AUC\[0-infinity\]= AUC\[0-t\] + Ct/lambda-z, Ct is the last measurable concentration and lamda-z is the terminal rate constant. AUC\[0-infinity\] is the sum of measurable and extrapolated parts.
Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
PK Endpoints: Pegfilgrastim T[Max]
The time of observing the peak concentration, calculated from the serum concentration vs. time profile of the individual subjects.
Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
PK Endpoints: Pegfilgrastim λz (Lambda-z)
Terminal rate constant: First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more nonzero plasma concentration values.
Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
PK Endpoints: Pegfilgrastim R^2 Adjusted
Goodness of fit statistic for the terminal phase, adjusted for the number of points used in the estimation of λz (lambda-z). R\^2 is the coefficient of determination and can range from 0 to 1, with higher values indicating greater predictability.
Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
PK Endpoints: Pegfilgrastim AUC[_%Extrap_Obs]
The residual area in percentage determined by the formula, \[(AUC\[0-infinity\]-AUC\[0-t\])/AUC\[0-infinity\]\] x 100.
Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
PK Endpoints: Pegfilgrastim t[1/2]
The terminal half-life calculated using the formula 0.693/(lambda-z)
Time frame: Venous blood samples (4 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) hours following 1st and 2nd dose, administration.
PD Endpoints for Baseline Non-adjusted ANC: E[Max]
Maximum measured absolute neutrophil count (ANC).
Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
PD Endpoints for Baseline Non-adjusted ANC: T[Max]
Area under the ANC versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.
Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
PD Endpoints for Baseline Non-adjusted ANC: AUEC[0-t]
Time to reach the maximum measured absolute neutrophil count (ANC)
Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
PD Endpoints for Baseline Adjusted ANC: E[Max]
Maximum measured absolute neutrophil count (ANC).
Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
PD Endpoints for Baseline Adjusted ANC: AUEC[0-t]
Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.
Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
PD Endpoints for Baseline Adjusted ANC: T[Max]
Time to reach the maximum measured absolute neutrophil count (ANC)
Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
PD Endpoints for Baseline Adjusted ANC: λz (Lambda-z)
First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more non-zero plasma concentration values.
Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
PD Endpoints for Baseline Adjusted ANC: t[1/2]
The terminal half-life will be calculated as 0.693/(lambda-z)
Time frame: Venous blood samples (2 mL each) were withdrawn at pre-dose and at 8, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), 96 (Day 5), 120 (Day 6), 144 (Day 7), 240 (Day 11), 336 (Day 15) and 504 (Day 22) following 1st and 2nd dose administration.
| Milestone | INTP5 Biosimilar Product | US Neulasta Reference Product |
|---|---|---|
| Started | 100 | 100 |
| Completed | 89 | 93 |
| Not completed | 11 | 7 |
| Withdrew: Withdrawal by subject | 7 | 4 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Medical grounds | 3 | 3 |
Immunogenicity (anti-drug antibody; ADA) data is presented for all subjects' samples collected and a descriptive analysis is provided for immunogenicity (ADA) data. Percentage incidence within + 10% of the expected ADA positivity incidence of Test (6% ADA in Test is anticipated from literature) is not considered clinically significant. Evaluation of immunogenicity is carried out in a tiered fashion: 1. Screening assay to assess if samples were positive or negative for anti-PegG-CSF. 2. Confirmatory assays for samples that were positive in the screening assay. The confirmatory assays assessed if antibodies were specific for INTP5, Neulasta, PEG and/or filgrastim. 3. Titer assay was performed to determine titer of the anti-PEG-GCSF antibody samples. 4. Neutralizing antibody (NAb) assay for those samples that were positive in the confirmatory assays to assess the neutralizing capability of the antibody to inhibit pegfilgrastim activity.
| Participants | INTP5 Biosimilar Product | US Neulasta Reference Product |
|---|---|---|
| Positive for Anti-Drug-Antibody | 10 | 9 |
| Positive in Neutralizing Anti-Drug-Antibody | 0 | 0 |
| No Anit-Drug Antibody Confirmed Positive Results | 84 | 91 |
Pharmacokinetic (PK) properties of the test and reference formulations were assessed by measuring serum Pegfilgrastim concentration. Maximum measured serum concentration, calculated from the serum concentration vs. time profile of the individual subjects.
| ng/mL | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| PK Endpoints: Pegfilgrastim C[Max] | 483.230 ± 175.1787 | 346.018 ± 150.4879 | 368.569 ± 223.3380 | 371.778 ± 263.4440 |
Area under the serum concentration vs. time curve, calculated by linear trapezoidal rule from measured data points from the time zero to the time of last quantified concentration.
| ng.h/mL | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| PK Endpoints: Pegfilgrastim AUC[0-t] | 22417.938 ± 9922.2648 | 13640.695 ± 6709.2752 | 16610.870 ± 11255.1296 | 15255.327 ± 11050.7580 |
Area under the serum concentration versus time curve from time zero to infinity. Where AUC\[0-infinity\]= AUC\[0-t\] + Ct/lambda-z, Ct is the last measurable concentration and lamda-z is the terminal rate constant. AUC\[0-infinity\] is the sum of measurable and extrapolated parts.
| ng.h/mL | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| PK Endpoints: Pegfilgrastim AUC[0-∞] | 22436.497 ± 9922.4383 | 13637.403 ± 6699.9736 | 16630.861 ± 11253.7406 | 15280.376 ± 11058.1142 |
The time of observing the peak concentration, calculated from the serum concentration vs. time profile of the individual subjects.
| h | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| PK Endpoints: Pegfilgrastim T[Max] | 22.405 ± 3.3758 | 20.800 ± 5.5936 | 22.226 ± 3.5298 | 23.111 ± 2.6667 |
Terminal rate constant: First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more nonzero plasma concentration values.
| 1/h | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| PK Endpoints: Pegfilgrastim λz (Lambda-z) | 0.021 ± 0.0071 | 0.025 ± 0.0142 | 0.022 ± 0.0058 | 0.019 ± 0.0074 |
Goodness of fit statistic for the terminal phase, adjusted for the number of points used in the estimation of λz (lambda-z). R\^2 is the coefficient of determination and can range from 0 to 1, with higher values indicating greater predictability.
| Coefficient of Determination | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| PK Endpoints: Pegfilgrastim R^2 Adjusted | 0.968 ± 0.0379 | 0.876 ± 0.133 | 0.974 ± 0.0245 | 0.879 ± 0.2339 |
The residual area in percentage determined by the formula, \[(AUC\[0-infinity\]-AUC\[0-t\])/AUC\[0-infinity\]\] x 100.
| percentage of AUC | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| PK Endpoints: Pegfilgrastim AUC[_%Extrap_Obs] | 0.115 ± 0.1106 | 0.644 ± 1.4428 | 0.230 ± 0.2672 | 0.266 ± 0.2664 |
The terminal half-life calculated using the formula 0.693/(lambda-z)
| h | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| PK Endpoints: Pegfilgrastim t[1/2] | 36.721 ± 11.0052 | 36.612 ± 19.6215 | 34.172 ± 8.8669 | 40.616 ± 14.6054 |
Maximum measured absolute neutrophil count (ANC).
| x10^3cells/uL | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| ADA-NEGATIVE | 40.72 ± 10.862 | 44.63 ± 11.077 | 38.34 ± 9.925 | 40.62 ± 8.963 |
| ADA-POSITIVE | 42.89 ± 10.512 | 46.53 ± 9.093 | 38.38 ± 8.211 | 44.96 ± 16.409 |
Area under the ANC versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.
| h | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| ADA-NEGATIVE | 64.710 ± 11.1076 | 59.587 ± 14.9170 | 63.182 ± 15.8763 | 64.637 ± 20.5772 |
| ADA-POSITIVE | 72.003 ± 0.0072 | 67.453 ± 15.7091 | 64.002 ± 12.0014 | 61.461 ± 29.9401 |
Time to reach the maximum measured absolute neutrophil count (ANC)
| h*ng/mL | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| ADA-NEGATIVE | 7107.14 ± 1481.971 | 7929.25 ± 1561.246 | 6718.70 ± 1361.957 | 7359.09 ± 1455.570 |
| ADA-POSITIVE | 7286.53 ± 1744.737 | 8539.99 ± 1522.935 | 6846.77 ± 763.675 | 7761.65 ± 1658.478 |
Maximum measured absolute neutrophil count (ANC).
| x10^3cells/uL | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| ADA-NEGATIVE | 36.50 ± 10.458 | 40.80 ± 11.038 | 33.35 ± 9.189 | 36.56 ± 8.755 |
| ADA-POSITIVE | 38.37 ± 9.548 | 42.50 ± 10.061 | 34.18 ± 8.503 | 40.76 ± 17.170 |
Area under the absolute neutrophil count (ANC) versus time curve from time zero to the last measurable concentration as calculated by linear trapezoidal method.
| x10^3cells*h/uL | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| ADA-NEGATIVE | 4920.26 ± 1339.674 | 5992.49 ± 1555.062 | 4389.55 ± 1140.655 | 5441.01 ± 1478.241 |
| ADA-POSITIVE | 4967.86 ± 1229.792 | 6539.58 ± 2202.473 | 4578.32 ± 1200.125 | 5676.92 ± 1991.456 |
Time to reach the maximum measured absolute neutrophil count (ANC)
| h | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| ADA-NEGATIVE | 64.617 ± 11.1482 | 59.735 ± 14.9546 | 65.553 ± 15.8887 | 65.043 ± 20.6610 |
| ADA-POSITIVE | 72.003 ± 0.0072 | 67.453 ± 15.7091 | 64.002 ± 12.0014 | 61.461 ± 29.9401 |
First order rate constant associated with the terminal (log-linear) portion of the curve. This was estimated via linear regression of time vs. log concentration. This parameter was calculated by linear least squares regression analysis using last three or more non-zero plasma concentration values.
| h | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| ADA-NEGATIVE | 0.01 ± 0.007 | 0.01 ± 0.006 | 0.01 ± 0.006 | 0.01 ± 0.006 |
| ADA-POSITIVE | 0.01 ± 0.006 | 0.01 ± 0.003 | 0.01 ± 0.004 | 0.01 ± 0.005 |
The terminal half-life will be calculated as 0.693/(lambda-z)
| h | INTP5 Dose 1 | INTP5 Dose 2 | US Neulasta Dose 1 | US Neulasta Dose 2 |
|---|---|---|---|---|
| ADA-NEGATIVE | 62.25 ± 28.847 | 64.13 ± 26.785 | 77.23 ± 86.239 | 76.02 ± 59.888 |
| ADA-POSITIVE | 67.03 ± 41.296 | 69.72 ± 25.447 | 81.74 ± 29.981 | 67.02 ± 22.706 |
Collected over 99 Days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| INTP5 Biosimilar Product | 0/100 (0%) | 0/100 (0%) | 32/100 (32%) |
| US Neulasta Reference Product | 1/100 (1%) | 1/100 (1%) | 37/100 (37%) |
| Event | INTP5 Biosimilar Product | US Neulasta Reference Product |
|---|---|---|
| deathGeneral disorders | 0/100 | 1/100 |
| Event | INTP5 Biosimilar Product | US Neulasta Reference Product |
|---|---|---|
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 16/100 | 15/100 |
| HeadacheNervous system disorders | 6/100 | 13/100 |
| VomitingGastrointestinal disorders | 5/100 | 5/100 |
| Injection site painGeneral disorders | 5/100 | 4/100 |
| InjuryInjury, poisoning and procedural complications | 0/100 | 3/100 |
| Red blood cells urine positiveInvestigations | 3/100 | 0/100 |
| DiarrhoeaGastrointestinal disorders | 0/100 | 2/100 |
| PyrexiaGeneral disorders | 2/100 | 0/100 |
| EosinophiliaBlood and lymphatic system disorders | 1/100 | 0/100 |
| Abdominal painGastrointestinal disorders | 1/100 | 0/100 |
| Age, Continuous(years) | INTP5 Biosimilar Product | US Neulasta Reference Product | Total |
|---|---|---|---|
| Mean | 31.5 ± 6.82 | 34.3 ± 6.05 | 32.9 ± 6.58 |
| Sex: Female, Male(Participants) | INTP5 Biosimilar Product | US Neulasta Reference Product | Total |
|---|---|---|---|
| Female | 40 | 40 | 80 |
| Male | 60 | 60 | 120 |
| Race (NIH/OMB)(Participants) | INTP5 Biosimilar Product | US Neulasta Reference Product | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 100 | 100 | 200 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | INTP5 Biosimilar Product | US Neulasta Reference Product | Total |
|---|---|---|---|
| India | 100 | 100 | 200 |
| Height(cm) | INTP5 Biosimilar Product | US Neulasta Reference Product | Total |
|---|---|---|---|
| Mean | 160.2 ± 8.48 | 160.1 ± 8.68 | 160.2 ± 8.56 |
| Weight(kg) | INTP5 Biosimilar Product | US Neulasta Reference Product | Total |
|---|---|---|---|
| Mean | 61.3 ± 8.31 | 62.6 ± 7.49 | 61.9 ± 7.92 |
| BMI(kg/m^2) | INTP5 Biosimilar Product | US Neulasta Reference Product | Total |
|---|---|---|---|
| Mean | 23.95 ± 3.069 | 24.51 ± 3.266 | 24.23 ± 3.173 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Jun 2018, 3 months.
Results were first posted in Oct 2019, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegfilgrastim
Intas Pharmaceuticals, Ltd.